Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04645069
Recruitment Status : Recruiting
First Posted : November 27, 2020
Last Update Posted : May 25, 2022
Information provided by (Responsible Party):
Adagene Inc

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : March 31, 2024
Estimated Study Completion Date : December 31, 2024